RxDoctor Payments Data

Mashail Manzur

Podiatrist · Tucker, GANPI 1689107807

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Stryker at 39.7% of the total. Reporting peaked in 2019 at $4,978 and has fallen 99.5% since, to $25 in 2025.

$6,663in general payments, 2019–2025

Across 74 payments — averaging $90.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Southern Edge Orthopaedics, Inc.$2K
  • Amniox Medical, Inc.$784
  • Biotissue Holdings Inc.$356
  • Medical Device Business Services, Inc.$320
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$144
  • plus $570 from 16 others

What the payments were for

  • Consulting fees$571%
  • Speaking & faculty fees$911%
  • Travel & lodging$1,38921%
  • Food & beverage$2,96444%
  • Education$2,16432%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,663 in reported general payments places this provider in the 80th percentile of 177 podiatrist providers in Georgia.

See all podiatrist providers in Georgia

Medicare billing

Part B allowed, 2024
$59,536
Medicare patients
155
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium79$2,143
Ciclopirox72$2,018
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip59$971
Methylprednisolone24$102
Meloxicam49$78
Gabapentin13$54

Paid to pharmacies, not to this prescriber.

Other podiatrist in Tucker

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →